|
|
|
SCIENTIFIC PUBLICATIONS
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. J Clin Oncol Aug 9:, 2010. [PubMed]
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. J Clin Oncol Aug 30:, 2010. [PubMed]
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
Shi L, Campbell G, Jones WD et al. Nature Biotechnol 28(8):827-38, 2010. [PubMed]
Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Mol Cancer Ther 9(5):1120-7, 2010. [PubMed]
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L. Breast Cancer Res 12(1):R5, 2010. [PubMed]
Genomic grade index is associated with response to chemotherapy in patients with breast cancer
Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L. J Clin Oncol 27(19):3185-91, 2009. [PubMed]
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Ann Oncol 19(12):2020-5, 2008. [PubMed]
Commercialized multigene predictors of clinical outcome for breast cancer
Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Oncologist 13(5):477-93, 2008. [PubMed]
CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer
Wu M, Soler DR, Abba MC, Nunez MI, Baer R, Hatzis C, Llombart-Cussac A, Llombart-Bosch A, Aldaz CM. Mol Cancer Res 5(12):1285-95, 2007. [PubMed]
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN and Pusztai L. J Clin Oncol 25:4414-22, 2007. [PubMed]
Microtubule associated protein (MAP)-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in ER-positive breast cancer
Andre F, Hatzis C, Anderson K, Sotirou C, Mazouni C, Mejia JA, Wang B, Hortobagyi G, Symmans W and Pusztai L. Clin Cancer Res 13:2061-7, 2007. [PubMed]
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN and Pusztai L. Breast Cancer Res Treat 2007. [PubMed]
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience
Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN and Buzdar AU. Cancer 110:1195-200, 2007. [PubMed]
Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice
Diaz LK, Cryns VL, Symmans WF and Sneige N. Adv Anat Pathol 14:419-30, 2007. [PubMed]
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Jr., Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L and Symmans WF. Lancet Oncol 8:203-11, 2007. [PubMed]
Gene-expression microarrays provide new prognostic and predictive tests for breast cancer
Gong Y, Symmans WF and Pusztai L. Pharmacogenomics 8:1359-1368, 2007. [PubMed]
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN and Pusztai L. J Clin Oncol 25:2650-5, 2007. [PubMed]
Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer
Peintinger F, Anderson K, Mazouni C, Kuerer HM, Hatzis C, Lin F, Hortobagyi GN, Symmans WF and Pusztai L. Clin Cancer Res 13:4078-82, 2007. [PubMed]
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer
Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L and Symmans WF. Br J Surg 2007. [PubMed]
Limitations of pharmacogenomic predictor discovery in Phase II clinical trials
Pusztai L. Pharmacogenomics 8:1443-8, 2007. [PubMed]
Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer
Pusztai L, Anderson K and Hess KR. Clin Cancer Res 13:6080-6, 2007. [PubMed]
Personalized medicine for breast cancer: Moving forward and going back.
Ross JS, Symmans W, Pusztai L and Hortobagyi G. Personalized Medicine 363-370, 2007. [ ]
Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes
Ross JS, Symmans WF, Pusztai L and Hortobagyi GN. Clin Cancer Res 13:2831-5, 2007. [PubMed]
A pathologist's perspective on emerging genomic tests for breast cancer
Symmans WF. Semin Oncol 34:S4-9, 2007. [PubMed]
Large-scale identification of novel transcripts in the human genome
Peters BA, St Croix B, Sjoblom T, Cummins JM, Silliman N, Ptak J, Saha S, Kinzler KW, Hatzis C and Velculescu VE. Genome Res 2007. [PubMed]
Breast Cancer Biomarkers
Ross JS, Symmans W, Pusztai L and Hortobagyi GN. Adv. Clin Chem. 40:99-125, 2006. [PubMed]
Chips to bedside: incorporation of microarray data into clinical practice
Pusztai L. Clin Cancer Res 12:7209-14, 2006. [PubMed]
Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer
Pusztai L and Esteva FJ. Cancer Invest 24:187-91, 2006. [PubMed]
Molecular classification of breast cancer: limitations and potential
Pusztai L, Mazouni C, Anderson K, Wu Y and Symmans WF. Oncologist 11:868-77, 2006. [PubMed]
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, Zhang L, Amur S, Bao W, Barbacioru CC, Lucas AB, Bertholet V, Boysen C, Bromley B, Brown D, Brunner A, Canales R, Cao XM, Cebula TA, Chen JJ, Cheng J, Chu TM, Chudin E, Corson J, Corton JC, Croner LJ, Davies C, Davison TS, Delenstarr G, Deng X, Dorris D, Eklund AC, Fan XH, Fang H, Fulmer-Smentek S, Fuscoe JC, Gallagher K, Ge W, Guo L, Guo X, Hager J, Haje PK, Han J, Han T, Harbottle HC, Harris SC, Hatchwell E, Hauser CA, Hester S, Hong H, Hurban P, Jackson SA, Ji H, Knight CR, Kuo WP, LeClerc JE, Levy S, Li QZ, Liu C, Liu Y, Lombardi MJ, Ma Y, Magnuson SR, Maqsodi B, McDaniel T, Mei N, Myklebost O, Ning B, Novoradovskaya N, Orr MS, Osborn TW, Papallo A, Patterson TA, Perkins RG, Peters EH, Peterson R, Philips KL, Pine PS, Pusztai L, Qian F, Ren H, Rosen M, Rosenzweig BA, Samaha RR, Schena M, Schroth GP, Shchegrova S, Smith DD, Staedtler F, Su Z, Sun H, Szallasi Z, Tezak Z, Thierry-Mieg D, Thompson KL, Tikhonova I, Turpaz Y, Vallanat B, Van C, Walker SJ, Wang SJ, Wang Y, Wolfinger R, Wong A, Wu J, Xiao C, Xie Q, Xu J, Yang W, Zhang L, Zhong S, Zong Y and Slikker W, Jr.. Nat Biotechnol 24:1151-61, 2006. [PubMed]
Do pharmacogenomic tests provide value to policy makers?
Shih YC and Pusztai L. Pharmacoeconomics 24:1173-7, 2006. [PubMed]
Genomic testing for sensitivity of breast cancer to hormonal therapy
Symmans WF. Clin Cancer Res 12:1954-5, 2006. [PubMed]
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN and Pusztai L. J Clin Oncol 24:4236-44, 2006. [PubMed]
DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design
Andre F, Mazouni C, Hortobagyi GN and Pusztai L. Biochim Biophys Acta 1766:197-204, 2006. [PubMed]
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre F and Pusztai L. Nat Clin Pract Oncol 3:621-32, 2006. [PubMed]
Reproducibility of gene expression signature-based predictions in replicate experiments
Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF and Pusztai L. Clin Cancer Res 12:1721-7, 2006. [PubMed]
Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
Pusztai L, Symmans FW and Hortobagyi GN. Breast Cancer 12:73-85, 2005. [PubMed]
Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips
Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W and Pusztai L. J Mol Diagn 7:357-67, 2005. [PubMed]
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN and Pusztai L. J Clin Oncol 22:2284-93, 2004. [PubMed]
Clinical trial design for microarray predictive marker discovery and assessment
Pusztai L and Hess KR. Ann Oncol 15:1731-7, 2004. [PubMed]
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors
Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN and Symmans WF. Clin Cancer Res 9:2406-15, 2003. [PubMed]
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN and Pusztai L. Cancer 97:2960-71, 2003. [PubMed]
|
|
|
|
